One infusion of natalizumab (300 mg or 3 mg/kg) vs placebo
Serious adverse events up to week 12 · Patients with active Crohn's disease
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).
1 finding from 1 review
- RR 0.93 [0.34, 2.49]1 study · 131 participantsLow